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Transplantation Centers using human cytome-
galovirus (HCMV) antigenemia-based preemp-
tive therapy will need to replace in the near future
the antigenemia assay with a more standardized
and automatable assay, such as a molecular
assay quantifying HCMV DNA in blood (DNAe-
mia). Thus, in view of replacing antigenemia with
clinically safe cutoff values, DNAemia levels
corresponding to antigenemia cutoffs guiding
HCMV preemptive therapy were determined
retrospectively in solid organ and hematopoietic
stem cell transplant recipients (HSCTR) using an
‘‘in-house’’ quantitative PCR (QPCR) method.
Since preemptive therapy had prevented appear-
ance of HCMV disease in all patients tested, DNA
cutoffs determined retrospectively had to be
considered as safe clinically as antigenemia cut-
offs used prospectively. However, in solid organ
transplant recipients (SOTR), initiating preemp-
tive therapy upon an antigenemia cutoff of
100 pp65-positive leukocytes, a DNAemia cutoff
of 300,000 copies/ml blood had positive and
negative predictive values of >90%, indicating
that a DNAemia cutoff could achieve, in terms of
prevention of HCMV disease, the same clinical
results as the antigenemia cutoff. In HSCTR,
initiating preemptive therapy upon first antige-
nemia positivity, a DNAemia cutoff of 10,000
copies/ml blood had a positive predictive value of
>90%, indicating that the great majority of
patients treated under the antigenemia guidance
would have been treated also using this DNA
cutoff. On the other hand, the negative predictive
value of 28.6% indicated that two out of three
HSCTR had been treated under the antigenemia
guidance having the same levels of viral DNA as
the untreated patients. The data suggest that a
quantitative cutoff could be adopted as a guiding
criterion for preemptive therapy also in HSCTR.
Regression analysis allowed to determine the
DNAemia (corresponding to QPCR) cutoff values
for two commercial assays tested both in solid
organ and HSCTR. Retrospective DNAemia cutoff
values will be verified for safety in prospective
trials. J. Med. Virol. 73:412–419, 2004.
 2004 Wiley-Liss, Inc.
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INTRODUCTION
Preemptive therapy is an effective approach to control
human cytomegalovirus (HCMV) infections in trans-
plant recipients, based on the administration of anti-
viral drugs upon detection of HCMV in blood, in view of
treating only patients undergoing active viral infection
and, thus, at risk of developing overt HCMV disease
[Einsele et al., 1995; Boeckh et al., 1996; Egan et al.,
1998; Ljungman et al., 1998; Kusne et al., 1999].
Preemptive therapy is currently started upon reaching
predetermined levels of viral load in solid organ
transplant recipients (SOTR), whereas in hematopoietic
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Istituto Superiore di Sanità, Progetto Multidisciplinare sulla
Terapia delle Malattie da Virus; Grant number: 0AG/F16; Grant
sponsor: Ministero dell’Istruzione, Università e Ricerca Scienti-
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stem cell transplant recipients (HSCTR) treatment is
started upon the first appearance of virus in blood
[Einsele et al., 1991; Gerna et al., 1995; Grossi et al.,
1995; Boeckh and Boivin, 1998; Razonable et al., 2002b].
One of the diagnostic assays used for preemptive
therapy has been antigenemia [Van der Bij et al., 1988;
Revello et al., 1989; Boeckh et al., 1992; Locatelli et al.,
1994], which, however, is not a direct marker of viral
replication, being based upon detection in peripheral
blood leukocytes of a viral protein (pp65) synthesized in
large excess in endothelial cells, and then transferred to
leukocytes [Britt and Vugler, 1987; Gerna et al., 2000b,
2003c]. In addition, antigenemia has been shown to
increase in level during antiviral treatment either
dissociated from a similar trend of viremia and DNA in
blood (DNAemia) in solid organ transplanted patients
with primary infection [Gerna et al., 1998b] and HSCTR
[Boeckh et al., 1996; Gerna et al., 2003b] or associated
with the rising viremia and DNAemia in hematopoietic
stem cell transplanted patients with steroid-treated
graft-versus-host disease [Nichols et al., 2001].
DNAemia, instead, appears to correlate better with the
presence of infectious virus in blood and with clinical
manifestations of viral infection [Gerna et al., 1998a,b,
2003a]. In addition, assays for DNAemia quantitation
can be standardized more easily and automated than
antigenemia.
For more than a decade, the preemptive therapy
approach to the treatment of HCMV infections in
transplant recipients at the University Hospital IRCCS
Policlinico San Matteo, Pavia, Italy, has been based
upon a cutoff of 100 pp65-positive/2105 leukocytes in
reactivated infections of SOTR, and upon the first
confirmed antigenemia positivity in primary HCMV
infections of SOTR as well as in HCMV infections of
HSCTR [Gerna et al., 2003a,b]. This approach has been
safe and has prevented consistently HCMV disease.
In this report, DNAemia levels present in patients
belonging to either transplanted patient population at
time of initiation of antigenemia-guided preemptive
therapy were reassured retrospectively. DNAemia
levels were determined by using an ‘‘in-house’’ quanti-
tative PCR (QPCR) method. Subsequently, in order to
match cutoff levels determined by the QPCR method to
commercially available molecular systems, a subset of
blood samples from transplanted patients assayed
previously by QPCR were tested by two commercial
assays. Then, regression analysis was used to extra-
polate comparable DNA cutoffs between the ‘‘in-house’’
method and the two commercial molecular assays.
MATERIALS AND METHODS
Patients
Initially, QPCR DNA was quantified retrospectively
in 35 SOTR with as many episodes of active HCMV
infection, 11 of which reached the antigenemia cutoff
level for treatment initiation (100 pp65-positive/2105
leukocytes), while the other 24 patients resolved the
infection spontaneously [Gerna et al., 2003a]. In addi-
tion, 56 HSCTR patients with as many episodes of
HCMV infection treated upon the first confirmed anti-
genemia and 19 HSCTR patients with as many episodes
of self-resolving (antigenemia not confirmed at the
following test) HCMV infection were evaluated retro-
spectively for DNAemia levels [Gerna et al., 2003b].
Then, sequential blood samples from 19 SOTR (13 heart
and 6 lung transplant recipients) and 23 HSCTR were
evaluated in parallel for HCMV DNAemia quantitation
by both QPCR and two commercial assays.
Viral DNA Assays
HCMV DNA was quantified by the ‘‘in-house’’ method
of QPCR [Gerna et al., 1994, 1998a] and the following
two commercial assays: the Digene Hybrid Capture1
System CMV DNA version 2.0 (HCS, Abbott Labora-
tories, Abbott Park, IL) and the COBAS1Amplicor CMV
MonitorTM Test (Amplicor, Roche Diagnostic System,
Pleasanton, CA). HCMV DNA was determined on whole
blood by QPCR, hybrid capture system (HCS) and
Amplicor-whole blood. In addition, HCMV DNA was
determined on plasma by Amplicor-plasma. HCS and
Amplicor-plasma were performed according to manu-
facturer’s instructions, and quantitative results were
referred to 1.0 ml whole blood or plasma, respectively.
For QPCR and Amplicor-whole blood, nucleic acids were
isolated from 100 ml whole blood using NucliSens
Isolation Kit (bioMerieux, Boxtel, The Netherlands).
DNA quantitation for QPCR was performed on 1/10 of
the elution product. Amplicor was adapted to whole
blood by diluting 1:8 with dilution buffer (as in the
plasma assay) the same nucleic acid extract. Internal
standard was then added and 50 ml of the solution
(corresponding to 12.5 ml whole blood) was submitted to
amplification. Then, the same procedure used for
Amplicor-plasma was followed. Uniformity of results
was achieved by expressing QPCR and Amplicor-whole
blood final results as HCMV DNA copies/ml whole blood.
Positive QPCR values <1,000 copies/ml were assigned
an arbitrary value of 500 copies/ml.
Statistical Analysis
Chi-square test was used to compare sensitivities of
the different assays, while Pearson’s correlation
between QPCR and the two commercial assays was
calculated. Regression curves were drawn to compare
QPCR cutoff values with those of the two commercial
assays.
RESULTS
Retrospective Determination of DNAemia
Cutoff Levels Upon the Start
of Preemptive Therapy
All transplanted patients undergoing antigenemia-
based preemptive therapy and examined retrospec-
tively for HCMV DNA had a favorable outcome of the
HCMV infection without the occurrence of HCMV dis-
ease. Therefore, the proposal of DNAemia cutoff levels,
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to be verified in prospective trials, was based on the
clinical safety of antigenemia-guided cutoffs, and DNA
cutoffs were selected to achieve the highest levels of
sensitivity, specificity, positive and negative predictive
values for detection of patients requiring treatment with
respect to antigenemia-based and clinically validated
cutoffs.
Retrospective analysis of DNAemia levels determined
by QPCR in 35 SOTR at the time of initiation of pre-
emptive therapy showed that more than 90% of patients
treated on the basis of antigenemia had DNA levels
above a cutoff of 300,000 copies/ml whole blood (10/
11 patients, sensitivity 90.9%), while more than 90% of
untreated patients had DNA levels below this cutoff (23/
24 patients, specificity 95.8%). This means that over 90%
of either treated or untreated patients would have been
managed by using DNAemia exactly as by using the
antigenemia cutoff with respect to preemptive therapy.
As shown in Figure 1A, individual DNA peak values
detected in patients treated on the basis of antigenemia
at the time when decision to treat was made were
included in the range of 176,000–2,260,000 (median
1,000,000) copies/ml, whereas those of untreated pa-
tients ranged from <1,000 to 366,200 (median 35,350)
copies/ml. Thus, a cutoff level of 300,000 HCMV DNA
copies/ml whole blood had a positive predictive value of
90.9% (10/11 patients) and a negative predictive value of
95.8% (23/24 patients) with respect to SOTR requiring
initiation of antigenemia-based preemptive therapy.
This cutoff appears worth verifying in prospective trials.
On the other hand, among HSCTR tested retro-
spectively at the time of preemptive therapy initiated
upon first antigenemia positivity, 11/56 patients
reached DNAemia levels which were above a cutoff of
10,000 DNA copies/ml whole blood (sensitivity 19.6%),
while 18/19 untreated patients, spontaneously clearing
the infection, had DNAemia levels below this cutoff
(specificity 94.7%). This means that an arbitrary cutoff
of 10,000 DNA copies/ml blood would have excluded
from treatment more than 90% of patients untreated on
the basis of antigenemia. Meanwhile, the same cutoff
would have induced start of treatment in about only 20%
of patients actually treated under the antigenemia
guidance, thus avoiding or delaying treatment of the
remaining patients. As shown in Figure 1B, individual
DNA peak values relevant to HSCTR treated on the
basis of first confirmed positive antigenemia were
included in the range of <1,000–99,400 (median 1,750)
HCMV DNA copies/ml, whereas those of patients
spontaneously clearing the infection in the absence of
Fig. 1. Peak DNAemia levels as determined by quantitative PCR (QPCR) in solid organ transplant
recipients (SOTR) and hematopoietic stem cell transplant recipients (HSCTR) either at the time when
antigenemia-based preemptive treatment was decided (treated), or following selection from serial results
in the absence of treatment (untreated). Cutoff DNA lines were extrapolated to select maximum levels of
positive and negative predictive values with respect to antigenemia-guided preemptive therapy.
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treatment ranged from <1,000 to 20,800 (median
<1,000) copies/ml. Thus, a cutoff level of 10,000 HCMV
DNA copies/ml whole blood showed a positive predictive
value of 91.7% (11/12 patients) and a negative predictive
value of 28.6% (18/63 patients) with respect to HSCTR
requiring preemptive therapy on the basis of first
confirmed antigenemia positivity. This data suggest
that in HSCTR the use of a quantitative (rather than a
qualitative) approach to preemptive therapy could avoid
unnecessary treatment of a fair aliquot of patients, thus
increasing the negative predictive value without chan-
ging the positive predictive value with respect to
qualitative antigenemia.
Correlation of QPCR and Commercial Assays
A group of samples from both transplanted patient
populations were tested for DNA both by QPCR and the
two commercial assays to collate viral DNA quantitation
obtained with different molecular methods and to define
cutoff values of commercial assays corresponding to
those previously determined by QPCR. On the whole,
585 samples were examined in parallel by QPCR and
HCS, 558 by QPCR and Amplicor-whole blood and 240
by QPCR and Amplicor-plasma (Table I). QPCR was not
significantly more sensitive than HCS (P> 0.05), detect-
ing HCMV DNA in 150/585 (25.6%) versus 125/585
(21.4%) blood samples examined. On the contrary,
QPCR showed higher sensitivity than Amplicor-whole
blood (P<0.01), detecting HCMV DNA in 183/558
(32.8%) versus 109/558 (19.5%) samples, and also higher
sensitivity than Amplicor-plasma, detecting HCMV in
137/240 (57.1%) samples tested versus 101/240 (42.1%)
(P<0.01).
As shown in Figure 2, the correlation between HCS
and QPCR was significant but markedly lower (P<0.01,
r¼0.59) than that found between QPCR and Amplicor-
whole blood (P<0.01, r¼ 0.91). In addition, the correla-
tion between Amplicor-plasma and QPCR on whole
blood was significant but lower (P<0.01, r¼ 0.52).
Regression curves were calculated to match QPCR
DNAemia cutoff values retrospectively determined with
those determined by using the two commercial assays.
On this basis, by using a QPCR cutoff of 300,000 viral
DNA copies/ml, the following DNAemia cutoff values
(95% CI) of commercial assays could be established for
SOTR: 117,169 (103,340–130,998) DNA copies/1.0 ml
whole blood for HCS, 168,100 (160,600–175,700) DNA
copies/ml whole blood for Amplicor-whole blood or
13,763 (10,750–17,016) DNA copies/1.0 ml plasma for
Amplicor-plasma, with the Amplicor-whole blood assay
showing the highest correlation with QPCR. For
HSCTR, by using a QPCR cutoff of 10,000 copies/ml,
cutoffs were lower by about one log10, or slightly more,
for the two commercial assays with respect to SOTR.
DISCUSSION
The request for virological monitoring of HCMV
infections in transplanted patients is increasing con-
tinuously in parallel with the increasing number of
transplantations performed at different transplanta-
tion centers. In this respect, standardized protocols for
HCMV infection surveillance and treatment as well as
automatable diagnostic assays are needed. In the last
decade, the antigenemia assay has been adopted as the
test of choice for monitoring HCMV infections in several
transplantation Centers in Italy and other European
countries. However, antigenemia is time-consuming
and requires a specific expertise. In addition, it does
not allow processing of a high number of specimens per
day. Hence, the need for developing standardized and
automated assays. At the moment, quantification of
HCMV DNAemia appears to be the best approach,
among molecular tests, for monitoring HCMV infec-
tions. In fact, it reflects directly virus replication and
may provide cutoff DNA levels for discriminating self-
clearing infections from infections at risk of developing
HCMV disease and, thus, requiring antiviral treatment
[Emery et al., 2000; Gerna et al., 2003a,b]. In this
respect, many Centers have chosen in the past to use
PCR instead of antigenemia [Einsele et al., 1995; Paya
et al., 2002]. However, safe cutoff values determined
clinically in patients in whom HCMV disease was
prevented, remain to be established.
In order to select clinically safe DNA cutoff levels to be
verified in prospective trials, HCMV DNA levels present
in blood of transplant recipients at time of initiation of
antigenemia-based preemptive therapy, were tested
and compared with peak values found in patients with
TABLE I. Human Cytomegalovirus (HCMV) DNA Detection in Blood Samples From Transplanted Patients, as Detected by
Different Assays
Commercial assay Result
No. (%) blood samples detected by QPCRa
P*Positive Negative
HCSb (n¼ 585) Positive 104 (17.8) 21 (3.6) >0.05
Negative 46 (7.8) 414 (70.8)
Amplicor-whole blood (n¼ 558) Positive 101 (18.1) 8 (1.4) <0.01
Negative 82 (14.7) 367 (65.8)
Amplicor-plasma (n¼ 240) Positive 92 (38.3) 9 (3.7) <0.01
Negative 45 (18.8) 94 (39.2)
*Chi-square test between QPCR and the different commercial assays.
aQPCR, quantitative PCR.
bHCS, Hybrid Capture System.
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self-resolving infections. These values were determined
by using the in-house QPCR method, which was
subsequently compared with the two commercial sys-
tems tested. To reflect better the in vivo condition, in the
last years HCMV DNA was quantitated on whole blood
[Gerna et al., 2000a] instead of peripheral blood
leukocytes [Gerna et al., 1994, 1998a]. More recently,
whole blood has been reported as the optimal sample for
HCMV DNA quantitative detection due to its higher
sensitivity and higher yield of HCMV DNA [Razonable
et al., 2002a].
The results described above indicate that HCS is as
sensitive as QPCR in detecting HCMV in blood.
However, from a quantitative standpoint, the correla-
tion between the two assays did not appear to be very
high. The best correlation was found between QPCR and
Amplicor when both assays were performed on the same
material (DNA isolated from whole blood), while the
lower correlation between QPCR and Amplicor-plasma
was likely to be related to the fact that HCMV in blood is
mostly cell-associated.
Cutoff values determined for SOTR by the two
commercial assays were approximated as follows:
100,000 copies/ml whole blood for HCS, 200,000 copies/
ml whole blood for Amplicor-whole blood, and 10,000
copies/ml plasma for Amplicor-plasma. These results
are about ten times higher than those published recently
on the comparison between levels of antigenemia and
DNAemia using quantitative real time PCR [Li et al.,
2003; Mengelle et al., 2003a,b]. However, in these
reports, DNA cutoffs were extrapolated from correlation
with antigenemia, without focusing on the patients’
outcome, and, given the lack of standardization of
antigenemia, cutoffs may not be comparable. In our
study, the levels of viral DNAemia were those actually
detected prior to the start of preemptive therapy, which
prevented consistently HCMV disease and, thus, were
verified as safe clinically. Cutoffs proposed by another
group taking care of the patient clinical outcome were
more similar to those calculated in the present study
[Hadaya et al., 2003].
The results of this study suggest that a cutoff value
might be adopted also for preemptive therapy of HSCTR.
In this patient population, if treatment has to be started
very early upon first appearance of virus in the blood (as
determined by the current policy in most hematopoietic
stem cell transplant recipients Centers), Amplicor-
whole blood and Amplicor-plasma appear to be less
sensitive than QPCR and HCS for early detection of
HCMV. However, as shown in Figure 1, several patients
undergoing antigenemia-guided preemptive therapy
reached DNA levels >10,000 HCMV DNA copies/ml
whole blood before initiation of treatment. Since none of
Fig. 2. Correlation of HCS (A), Amplicor-whole blood (B), and
Amplicor-plasma (C) with the ‘‘in-house’’ QPCR. Regression curves
with 95% CI are shown. Retrospectively determined QPCR DNAemia
cutoff values were interpolated on regression curves to determine the
corresponding DNAemia cutoff values (dotted lines) of the two
commercial assays tested for both SOTR and HSCTR. Correlation
coefficient (r) and number (n) of blood samples tested are reported for
each graph.
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these patients developed symptomatic disease, it is
suggested that preemptive therapy may be delayed
safely also in HSCTR until reaching a predetermined
cutoff value, in order to avoid treatment of self-resolving
infections. The interim analysis of an ongoing prospec-
tive trial, designed in our department to verify the
clinical utility and safety of this DNAemia cutoff value in
HSCTR, indicates that, using this approach, a fair
number of patients will avoid unnecessary treatment
due to self resolving HCMV infections (unpublished
results).
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